Total
(n=357; n (%))
Cryptococcal antigen (+)
 (n=30; n (%))
Cryptococcal antigen (-)
(n=327; n (%))
P-value
Sex        
Female 164 (46) 17 (56.7) 147 (45.0) 0.218
Male 193 (54) 13 (43.3) 180 (55.0)  
Age (years); median (IQR) 38 (31-43) 38 (31-41) 38 (31-43) 0.896
CD4 count (cells/μL); median (IQR) 28 (14-53) 15 (7-23) 32 (14-58) <0.001
< 50 cells/μL 257 (72) 28 (93.3)          231 (70.6) <0.008
BMI kg/m2; median (IQR) 18.3 (16.6-20.1) 16.7 (14.7-18.5) 18.4 (16.7-20.3) 0.0009
< 16 kg/m2 72 (20.2) 12 (40.0) 60 (18.6) 0.005
Started on ART 337 (94.4) 28 (93.3) 309 (94.5) 0.791
ART regimen (n=337)       0.808
D4T/3TC/NVP 146 (43.3%) 11 (39.3) 135 (43.7)  
D4T/3TC/EFV 174 (51.6%) 16 (57.1) 158 (51.1)  
Other 17 (5.0%) 1 (3.6) 16 (5.2)  
ART: Antiretroviral Treatment; BMI: Body Mass Index; CM: Cryptococcal Meningitis; D4T: Stavudine; EFV: Efavirenz; IQR: Interquartile Range; NVP: Nevirapine; 3TC: Lamivudine
Table 1: Baseline characteristics of individuals screened for serum cryptococcal antigen (sCrAg) prior to ART initiation with a CD4 count < 100 cells/μL, Phnom Penh, 2008-2012 (N=357).